%0 Journal Article %A Courtney Voss %A Sally Esmail %A Xuguang Liu %A Michael J. Knauer %A Suzanne Ackloo %A Tomonori Kaneko %A Lori Lowes %A Peter Stogios %A Almagul Seitova %A Ashley Hutchinson %A Farhad Yusifov %A Tatiana Skarina %A Elena Evdokimova %A Peter Loppnau %A Pegah Ghiabi %A Taraneh Haijian %A Shanshan Zhong %A Husam Abdoh %A Benjamin D. Hedley %A Vipin Bhayana %A Claudio M. Martin %A Marat Slessarev %A Benjamin Chin-Yee %A Douglas D. Fraser %A Ian Chin-Yee %A Shawn S-C. Li %T Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants %D 2021 %R 10.1101/2021.03.16.21253716 %J medRxiv %P 2021.03.16.21253716 %X BACKGROUND The role of humoral immunity in the coronavirus disease 2019 (COVID-19) is not fully understood owing, in large part, to the complexity of antibodies produced in response to the SARS-CoV-2 infection. There is a pressing need for serology tests to assess patient-specific antibody response and predict clinical outcome.METHODS Using SARS-CoV-2 proteome and peptide microarrays, we screened 146 COVID-19 patients plasma samples to identify antigens and epitopes. This enabled us to develop a master epitope array and an epitope-specific agglutination assay to gauge antibody responses systematically and with high resolution.RESULTS We identified 54 linear epitopes from the Spike (S) and Nucleocapsid (N) protein and showed that epitopes enabled higher resolution antibody profiling than protein antigens. Specifically, we found that antibody responses to the S(811-825), S(881-895) and N(156-170) epitopes negatively or positively correlated with clinical severity or patient survival. Moreover, we found that the P681H and S235F mutations associated with the coronavirus variant B.1.1.7 altered the specificity of the corresponding epitopes.CONCLUSIONS Epitope-resolved antibody testing not only offers a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, it may also be used as predictor of clinical outcome. The epitope peptides can be readily modified to detect antibodies against variants in both the peptide array and latex agglutination formats.FUNDING Ontario Research Fund (ORF)-COVID-19 Rapid Research Fund, the Toronto COVID-19 Action Fund, Western University, the Lawson Health Research Institute, the London Health Sciences Foundation, and the AMOSO Innovation Fund.Competing Interest StatementSE, CV, XL and SSCL are inventors in a provisional patent submitted by Western UniversityFunding StatementGrant funding to support research: Ontario Research Fund (ORF)-COVID-19 Rapid Research Fund, the Toronto COVID-19 Action Fund, Western University, the Lawson Health Research Institute, the London Health Sciences Foundation, and the AMOSO Innovation Fund. No external funding received for data monitoring board, study design, manuscript preparation, or statistical analysisAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were collected following a protocol (study number: 116284) approved by the Research Ethics Board (REB) of Western University. The plasma samples were de-identified prior to transfer from the Laboratory of Clinical Medicine (London Health Sciences Center, London, Canada) to a biosafety Level 3 (CL3) lab (ImPaKT, Western University) following Transportation of Dangerous Goods (TDG) guidelines. All plasma samples were heat-inactivated at 56 oC for 30 minutes at the ImPaKT CL3 facility as per Western university biosafety regulation. Heat inactivated plasma samples were then transferred to the testing laboratory. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary data available upon request %U https://www.medrxiv.org/content/medrxiv/early/2021/03/20/2021.03.16.21253716.full.pdf